JO3442B1 - مضادات ذات نوع فرعي من مستقبل سوماتوستاتين 5 (sstr5) - Google Patents

مضادات ذات نوع فرعي من مستقبل سوماتوستاتين 5 (sstr5)

Info

Publication number
JO3442B1
JO3442B1 JOP/2014/0283A JOP20140283A JO3442B1 JO 3442 B1 JO3442 B1 JO 3442B1 JO P20140283 A JOP20140283 A JO P20140283A JO 3442 B1 JO3442 B1 JO 3442B1
Authority
JO
Jordan
Prior art keywords
sstr5
antagonists
compound
receptor subtype
somatostatin receptor
Prior art date
Application number
JOP/2014/0283A
Other languages
English (en)
Inventor
Shizuo Kasai
Hideki Hirose
Asato Kina
Tohru Yamashita
Yoichi Nishikawa
Takeshi Yamasaki
Original Assignee
Takeda Pharmaceuticals Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takeda Pharmaceuticals Co filed Critical Takeda Pharmaceuticals Co
Application granted granted Critical
Publication of JO3442B1 publication Critical patent/JO3442B1/ar

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

<strong>يتعلق الاختراع الحالي بتوفير مركب له فعل مضاد </strong><span dir="LTR">SSTR5</span><strong> واستخدام المركب كدواء. على وجه التحديد، مركب يتم التعبير عنه بواسطة الصيغة التالية:</strong> <span dir="LTR"><img alt="??????? PT38-0003 ?????? 2013-20982620131007----00850075251302101257??20131007102827201310071027595150__________PT_84" src="file:///C:/Users/Darwish.Q/AppData/Local/Temp/msohtmlclip1/01/clip_image002.png" /></span> <strong>حيث يكون كل رمز كما تم التحديد في هذه الوثيقة،</strong> <strong> أو ملح منه، ويتم توفير دواء يشتمل على المركب أو ملح منه، واستخدام المركب أو ملح منه كعامل للوقاية من أو علاج مرض السكر. </strong>
JOP/2014/0283A 2013-10-07 2014-10-02 مضادات ذات نوع فرعي من مستقبل سوماتوستاتين 5 (sstr5) JO3442B1 (ar)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2013209826 2013-10-07

Publications (1)

Publication Number Publication Date
JO3442B1 true JO3442B1 (ar) 2019-10-20

Family

ID=51842719

Family Applications (1)

Application Number Title Priority Date Filing Date
JOP/2014/0283A JO3442B1 (ar) 2013-10-07 2014-10-02 مضادات ذات نوع فرعي من مستقبل سوماتوستاتين 5 (sstr5)

Country Status (24)

Country Link
US (2) US9353108B2 (ar)
EP (1) EP3055309B1 (ar)
JP (1) JP6411520B2 (ar)
CN (1) CN105612158B (ar)
AR (1) AR097932A1 (ar)
BR (1) BR112016007620B1 (ar)
CA (1) CA2926544C (ar)
CY (1) CY1121163T1 (ar)
DK (1) DK3055309T3 (ar)
ES (1) ES2687102T3 (ar)
HR (1) HRP20181372T1 (ar)
HU (1) HUE039386T2 (ar)
JO (1) JO3442B1 (ar)
LT (1) LT3055309T (ar)
PL (1) PL3055309T3 (ar)
PT (1) PT3055309T (ar)
RS (1) RS57743B1 (ar)
RU (1) RU2671958C2 (ar)
SI (1) SI3055309T1 (ar)
SM (1) SMT201800461T1 (ar)
TR (1) TR201810506T4 (ar)
TW (1) TWI648276B (ar)
UY (1) UY35774A (ar)
WO (1) WO2015052910A1 (ar)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6247697B2 (ja) * 2013-03-14 2017-12-13 武田薬品工業株式会社 スピロアゼチジンイソキサゾール誘導体及びそのｓｓｔｒ５アンタゴニストとしての使用
WO2016087352A1 (en) * 2014-12-02 2016-06-09 F. Hoffmann-La Roche Ag Novel piperidine derivatives
TW201712012A (zh) 2015-06-16 2017-04-01 美國禮來大藥廠 ２－側氧基－１，３，８－三氮雜螺［４．５］癸－３－基羧酸衍生物
BR112022006546A2 (pt) 2019-10-07 2022-08-30 Kallyope Inc Agonistas de gpr119
CA3173731A1 (en) 2020-02-28 2021-09-02 Kallyope, Inc. Gpr40 agonists
TW202207929A (zh) * 2020-05-13 2022-03-01 日商思可海雅藥品股份有限公司 膽道系疾病的診斷輔助、預防或治療劑
CN116323608A (zh) 2020-05-19 2023-06-23 卡尔优普公司 Ampk活化剂
EP4172162A4 (en) 2020-06-26 2024-08-07 Kallyope, Inc. AMPK ACTIVATORS
CN116354961B (zh) * 2021-12-27 2025-07-25 中国科学院上海药物研究所 生长抑素受体5拮抗剂及其药物组合物及用途
EP4534083A4 (en) * 2022-05-30 2025-11-19 Scinnohub Pharmaceutical Co Ltd USE OF A TETRAHYDRONAPHTYRIDINE DERIVATIVE FOR THE PREPARATION OF A MEDICINAL PRODUCT FOR THE PREVENTION AND TREATMENT OF DISEASES RELATED TO ADHESION
WO2024204277A1 (ja) * 2023-03-27 2024-10-03 株式会社スコヒアファーマ 成長ホルモン分泌促進剤

Family Cites Families (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5356906A (en) 1989-10-27 1994-10-18 The Du Pont Merck Pharmaceutical Company (N-phthalimidoalkyl) piperidines useful as treatments for psychosis
CN1072649C (zh) 1995-09-13 2001-10-10 武田药品工业株式会社 苯并氧杂吖庚因化合物,其生产方法和用途
US20030187023A1 (en) 2000-07-17 2003-10-02 Keiji Kubo Sulfone derivatives, process for their production and use thereof
WO2003027114A1 (en) 2001-09-24 2003-04-03 Bayer Pharmaceuticals Corporation Preparation and use of 1,5,6,7-tetrahydropyrrolo[3,2-c]pyridine derivatives for treatment of obesity
RU2004112787A (ru) * 2001-09-26 2005-10-10 Байер Фармасьютикалс Корпорейшн (US) Производные 1,6-нафтиридина как противодиабетические средства
TW200302225A (en) 2001-12-04 2003-08-01 Bristol Myers Squibb Co Substituted amino methyl factor Xa inhibitors
EP1556032A1 (en) 2002-11-01 2005-07-27 Takeda Pharmaceutical Company Limited Agent for preventing or treating neuropathy
EP1559422B1 (en) 2002-11-08 2014-04-30 Takeda Pharmaceutical Company Limited Receptor function controlling agent
WO2004048363A1 (ja) 2002-11-22 2004-06-10 Takeda Pharmaceutical Company Limited イミダゾール誘導体、その製造法および用途
WO2004080966A1 (ja) 2003-03-14 2004-09-23 Ono Pharmaceutical Co., Ltd. 含窒素複素環誘導体およびそれらを有効成分とする薬剤
EP1630152A4 (en) 2003-05-30 2009-09-23 Takeda Pharmaceutical CONDENSED CYCLIC COMPOUND
US7534887B2 (en) 2003-09-30 2009-05-19 Takeda Pharmaceutical Company Limited Thiazoline derivative and use of the same
RU2006120084A (ru) 2003-11-10 2008-01-10 Шеринг Акциенгезельшафт (De) Бензилэфирамины, полезные как антагонисты ccr-5
EP1695961A4 (en) 2003-12-17 2007-10-24 Takeda Pharmaceutical UREA DERIVATIVE, METHOD FOR THE PRODUCTION AND THEIR USE
CA2551610A1 (en) 2003-12-25 2005-07-14 Takeda Pharmaceutical Company Limited 3-(4-benzyloxyphenyl)propanoic acid derivatives
JP4855777B2 (ja) 2003-12-26 2012-01-18 武田薬品工業株式会社 フェニルプロパン酸誘導体
WO2005087710A1 (ja) 2004-03-15 2005-09-22 Takeda Pharmaceutical Company Limited アミノフェニルプロパン酸誘導体
EP2253315A1 (en) 2004-03-30 2010-11-24 Takeda Pharmaceutical Company Limited Alkoxyphenylpropanoic acid derivatives
TWI396686B (zh) 2004-05-21 2013-05-21 Takeda Pharmaceutical 環狀醯胺衍生物、以及其製品和用法
JP5094394B2 (ja) 2005-04-20 2012-12-12 武田薬品工業株式会社 縮合複素環化合物
EP1916234B1 (en) 2005-07-29 2014-11-12 Takeda Pharmaceutical Company Limited Cyclopropanecarboxylic acid compound
EP1911738A4 (en) 2005-07-29 2009-12-16 Takeda Pharmaceutical COMPOUND OF PHENOXYALKANOIC ACID
TW200740435A (en) 2005-08-10 2007-11-01 Takeda Pharmaceuticals Co Therapeutic agent for diabetes
JP2007063225A (ja) 2005-09-01 2007-03-15 Takeda Chem Ind Ltd イミダゾピリジン化合物
CL2007001873A1 (es) 2006-06-27 2008-01-04 Takeda Pharmaceutical Acido((3s))-6-((¨2,6-dimetil-4-(3-(metilsulfonil)-propoxi)bifenil-3-il)metoxi-2,3-dihidro-1-benzofuran-3-il)acetico o una sal del mismo
KR101117931B1 (ko) 2006-08-15 2012-04-12 에프. 호프만-라 로슈 아게 페닐, 피리딘 및 퀴놀린 유도체
US8492405B2 (en) 2006-10-18 2013-07-23 Takeda Pharmaceutical Company Limited Glucokinase-activating fused heterocyclic compounds and methods of treating diabetes and obesity
UA97257C2 (en) 2006-10-19 2012-01-25 Такеда Фармасьютикал Компани Лимитед Indole derivatives
JPWO2008093639A1 (ja) 2007-01-29 2010-05-20 武田薬品工業株式会社 ピラゾール化合物
MX2009008103A (es) 2007-02-09 2009-08-18 Takeda Pharmaceutical Compuestos anulares fusionados como agonistas parciales de prar-gamma.
US7862825B2 (en) 2007-02-21 2011-01-04 Mladen Vranic Method of controlling tight blood glucose by somatostatin receptor antagonists
US7799806B2 (en) * 2007-04-04 2010-09-21 Hoffmann-La Roche Inc. Substituted n-benzyl piperidines as somatostatin receptor modulators
WO2008136428A1 (ja) 2007-04-27 2008-11-13 Takeda Pharmaceutical Company Limited 含窒素５員複素環化合物
US20080306116A1 (en) * 2007-06-08 2008-12-11 Christ Andreas D Aryloxazole, aryloxadiazole and benzimidazole derivatives
EP2157859A4 (en) 2007-06-19 2011-01-12 Takeda Pharmaceutical INDAZOL COMPOUNDS FOR THE ACTIVATION OF GLUCCOKINASE
TW200918062A (en) * 2007-09-12 2009-05-01 Wyeth Corp Azacyclylisoquinolinone and-isoindolinone derivatives as histamine-3 antagonists
WO2010129729A1 (en) 2009-05-07 2010-11-11 Merck Sharp & Dohme Corp. Substituted spirocyclic amines useful as antidiabetic compounds
US8742110B2 (en) 2010-08-18 2014-06-03 Merck Sharp & Dohme Corp. Spiroxazolidinone compounds
EP2643311A1 (en) 2010-11-26 2013-10-02 Lupin Limited Bicyclic gpr119 modulators
JP6247697B2 (ja) 2013-03-14 2017-12-13 武田薬品工業株式会社 スピロアゼチジンイソキサゾール誘導体及びそのｓｓｔｒ５アンタゴニストとしての使用
RS58321B1 (sr) 2013-10-29 2019-03-29 Takeda Pharmaceuticals Co Heterociklično jedinjenje

Also Published As

Publication number Publication date
HUE039386T2 (hu) 2018-12-28
EP3055309B1 (en) 2018-06-13
CA2926544A1 (en) 2015-04-16
WO2015052910A1 (en) 2015-04-16
JP6411520B2 (ja) 2018-10-24
ES2687102T3 (es) 2018-10-23
RU2016117732A (ru) 2017-11-15
RU2671958C2 (ru) 2018-11-08
CN105612158A (zh) 2016-05-25
TW201536784A (zh) 2015-10-01
PT3055309T (pt) 2018-10-01
HRP20181372T1 (hr) 2018-10-19
SI3055309T1 (sl) 2018-10-30
US9751878B2 (en) 2017-09-05
UY35774A (es) 2015-05-29
US20160237087A1 (en) 2016-08-18
US20150099777A1 (en) 2015-04-09
BR112016007620A2 (pt) 2017-08-01
SMT201800461T1 (it) 2018-11-09
CA2926544C (en) 2021-07-06
LT3055309T (lt) 2018-08-27
JP2016531950A (ja) 2016-10-13
RS57743B1 (sr) 2018-12-31
BR112016007620B1 (pt) 2020-05-26
EP3055309A1 (en) 2016-08-17
DK3055309T3 (en) 2018-08-27
US9353108B2 (en) 2016-05-31
CN105612158B (zh) 2017-06-30
TR201810506T4 (tr) 2018-08-27
CY1121163T1 (el) 2020-05-29
AR097932A1 (es) 2016-04-20
PL3055309T3 (pl) 2018-10-31
TWI648276B (zh) 2019-01-21

Similar Documents

Publication Publication Date Title
PH12016501582A1 (en) Fused heterocyclic compound
PH12016501614A1 (en) Heterocyclic compound
MX2019010531A (es) Compuesto peptidico.
CY1121163T1 (el) Ανταγωνιστες υποδοχεα σωματοστατινης υποτυπου 5 (sstr5)
PH12014502857A1 (en) Analogs of glucagon exhibiting gip receptor activity
PH12015502031B1 (en) Tetrahydropyrrolothiazine compounds
MX2014015558A (es) Analogos de glucagon que exhiben actividad del receptor gip.
NZ629025A (en) Naphthyridine derivatives useful as alpha-v-beta-6 integrin antagonists
MX2016004088A (es) Compuesto que tiene actividad agonistica del receptor de somatostatina y uso farmaceutico del mismo.
PH12015501363B1 (en) Chloro-pyrazine carboxamide derivatives with epithelial sodium channel blocking activity
TN2016000567A1 (en) Heterocyclic compounds and their use as retinoid-related orphan receptor (ror) gamma-t inhibitors
MY152946A (en) Fused ring compound and use thereof
EA201692433A1 (ru) Соединения ppar для применения при лечении фиброзных заболеваний
AR128158A2 (es) Compuesto heterocíclico
EA201370149A1 (ru) Антагонисты рецептора
TN2017000097A1 (en) Heterocyclic compound
SG10201805896SA (en) PPARγ AGONISTS FOR TREATMENT OF MULTIPLE SCLEROSIS
EA201591645A1 (ru) Hантагонисты, имеющие феноксипиперидиновое ядро в структуре
NZ732704A (en) Quinoline carboxamides for use in the treatment of leukemia
PH12015502703A1 (en) Pharmaceutical compositions
NZ715554A (en) Method of treating hypertrophic cardiomyopathy
UA86566U (en) N-hydroxyhomoazaadamantanone and dioxomolybdenum complex thereof
IN2013MU02610A (ar)
UA90817U (uk) Сполука 1,1-діетилкарбокси-2-трифторметил-2-(5&#39;-бромуридил-1&#39;-)етилен з потенційними фізіологічними властивостями
UA87694U (uk) Сполука 4,5,6,7-тетрагідро-3н-2-n-(пара-метоксифенациламіно)-азепіну гідрохлорид з потенційними фізіологічними властивостями